Patents by Inventor Richard S. Blumberg
Richard S. Blumberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11591300Abstract: Provided herein are methods and compositions related to a method of stimulating the immune system in a subject in need thereof by administering an agent that increases the level or activity of indoleamine 2,3-dioxygenase (IDO1) and/or aryl hydrocarbon receptor (Ahr).Type: GrantFiled: December 21, 2018Date of Patent: February 28, 2023Assignee: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Shankar S. Iyer, Amit Ghandi, Amadeu Llebaria
-
Publication number: 20220298241Abstract: The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor. In certain embodiments, the FcRn inhibitor is an anti-FcRn antibody or antigen-binding fragment thereof.Type: ApplicationFiled: May 18, 2020Publication date: September 22, 2022Applicant: Alexion Pharmaceuticals, Inc.Inventors: Laurence J. Blumberg, Richard S. Blumberg, John Humphries
-
Publication number: 20220025040Abstract: Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.Type: ApplicationFiled: December 9, 2019Publication date: January 27, 2022Inventors: Richard S. Blumberg, Yu-Hwa Huang, Amit Gandhi, Monica Bertagnolli, Charles Yoon, Robert George Edward Holgate, Arron Robert Hearn, Susan Dana Jones
-
Publication number: 20210347887Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.Type: ApplicationFiled: March 9, 2021Publication date: November 11, 2021Applicant: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
-
Publication number: 20210139582Abstract: The technology described herein is directed to immunotherapy agents for autoimmune disease, cancer, or allergy. In some embodiments, the immunotherapy agent comprises a bispecific antibody construct that specifically binds FcRn and a Type I or Type II Fc? T receptor. In some embodiments the bispecific antibody construct is a DvD-Ig construct. Also described herein are methods for treating autoimmune disease, cancer, or allergy, comprising administering an effective amount of a bispecific antibody construct to patient in need thereof.Type: ApplicationFiled: February 13, 2019Publication date: May 13, 2021Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Michal PYZIK, Jonathan HUBBARD, Amit GANDHI
-
Publication number: 20210062160Abstract: In alternative embodiments, provided are compositions, products of manufacture and methods for treating, ameliorating and preventing infections, disorders and conditions in animals including: delivering a (i) bacteriophage (ii) prophage, the phagemid or phage-like particle, (iii) general transducing agent (GTA), or small, tailed bacteriophage-like particle, (iv) Metamorphosis Associated Contractile structure (MACs) or (v) phage-derived product into a tissue, or the blood stream or lymphatic system of the animal, e.g., the mammal; or delivering to a tissue or organ of the animal; or treating a bacterial or viral infection in the animal; generating an immune response in the animal; or treating a disease or condition in an individual in need thereof; or delivering a payload or a composition, e.g., in vivo, to the animal, or labelling, tagging or coating a cell in vivo in the animal.Type: ApplicationFiled: January 9, 2018Publication date: March 4, 2021Inventors: Forest ROHWER, Jeremy J. BARR, Richard S. BLUMBERG, Kristi D. BAKER
-
Publication number: 20210009535Abstract: Provided herein are methods and compositions related to a method of stimulating the immune system in a subject in need thereof by administering an agent that increases the level or activity of indoleamine 2,3-dioxygenase (IDO1) and/or aryl hydrocarbon receptor (Ahr).Type: ApplicationFiled: December 21, 2018Publication date: January 14, 2021Applicant: The Brigham and Women's Hospital, Inc.Inventors: Richard S. BLUMBERG, Shankar S. IYER, Amit GHANDI, Amadeu LLEBARIA
-
Patent number: 10822417Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.Type: GrantFiled: April 25, 2017Date of Patent: November 3, 2020Assignee: Syntimmune, Inc.Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George E. Holgate, Timothy D. Jones, Arron R. Hearn
-
Publication number: 20200241001Abstract: Described herein are methods, assays and systems for selecting subjects with immune-mediated diseases who would optimally respond to anti-FcRn therapies and administering effective amounts of compositions comprising anti-FcRn agents for treating, inhibiting and/or reducing the symptoms of immune-mediated diseases in subjects.Type: ApplicationFiled: August 27, 2019Publication date: July 30, 2020Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Kristi BAKER, Timo RATH
-
Publication number: 20200207854Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: February 25, 2020Publication date: July 2, 2020Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
-
Publication number: 20200181262Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: ApplicationFiled: February 25, 2020Publication date: June 11, 2020Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan D. Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
-
Patent number: 10626175Abstract: Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.Type: GrantFiled: November 13, 2017Date of Patent: April 21, 2020Assignee: SYNTIMMUNE, INC.Inventors: Laurence J. Blumberg, Richard S. Blumberg, Susan Dana Jones, Derry Roopenian, Robert George Edward Holgate, Timothy David Jones, Arron Robert Hearn
-
Publication number: 20200095284Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.Type: ApplicationFiled: November 6, 2019Publication date: March 26, 2020Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: RICHARD S. BLUMBERG, VIJAY K. KUCHROO, YU-HWA HUANG, CHEN ZHU, ANA C. ANDERSON
-
Patent number: 10588935Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.Type: GrantFiled: March 6, 2019Date of Patent: March 17, 2020Assignees: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin McDonnell, Rosa Maria Silva Garcia Grenha
-
Publication number: 20200040076Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.Type: ApplicationFiled: October 10, 2019Publication date: February 6, 2020Applicant: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
-
Publication number: 20200031928Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.Type: ApplicationFiled: October 1, 2019Publication date: January 30, 2020Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI
-
Publication number: 20200023034Abstract: The invention provided herein includes isolated polypeptides that specifically block the interaction between neonatal Fc receptor (FcRn) and albumin. Blocking the interaction treats diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties wherein it is deemed desirable to decrease albumin levels. Accordingly, also provided are methods of using these isolated polypeptides to treat various diseases and conditions caused by increased amounts of albumin or modified albumin that possesses pathogenic properties. The invention provided herein also includes isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on an FcRn alpha 3 domain. These can be useful for tracking FcRn without inhibiting IgG or albumin binding or function. Accordingly, the invention also includes methods and systems to track FcRn without inhibiting IgG or albumin binding or function.Type: ApplicationFiled: March 6, 2019Publication date: January 23, 2020Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BIOGEN MA INC.Inventors: Richard S. Blumberg, Timo Rath, Kristi Baker, Adam Mezo, Zachary Taylor, Kevin Mcdonnell, Rosa Maria Silva Garcia Grenha
-
Publication number: 20200024343Abstract: Described herein are compositions for increasing IL-12 production comprising IgG or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing IL-12 production comprising an agent that inhibits signaling mediated by interaction between FcRn and IgG and uses of said compositions for treating autoimmune diseases. Further described herein are methods for assessing efficacy of treatment by monitoring levels of various cytokines in the subject.Type: ApplicationFiled: February 20, 2019Publication date: January 23, 2020Applicant: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Kristi Baker, Timo Rath
-
Publication number: 20200010543Abstract: As demonstrated herein, soluble human FcRn binds to AFP with affinities greater than observed with albumin, and is able to interfere with FcRn-mediated protection of and functional associations with IgG. Accordingly, provided herein, in some aspects, are compositions and methods to inhibit FcRn and AFP interactions in diseases or disorders where elevated AFP levels are associated with immunosuppression. Also provided herein, in some aspects, are compositions and methods to enhance or potentiate FcRn and AFP interactions in diseases or disorders with decreased AFP levels or diseases or disorders where increasing AFP levels increasing with immunosuppression.Type: ApplicationFiled: February 25, 2019Publication date: January 9, 2020Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventors: Richard S. BLUMBERG, Kristi BAKER, Michal PYZIK, Amit GANDHI
-
Patent number: 10513540Abstract: Described herein are compositions and methods for the modulation of T-cell tolerance, which can be upregulated or down regulated by concurrent enhancement or inhibition of CEACAM1/TIM3 interactions. As described herein, the discovery that CEACAM1 is a direct ligand of TIM3 and vice versa has been shown in cis and in trans. In addition, as demonstrated herein, CEACAM1 and TIM3 are co-regulated during the course of T-cell activation.Type: GrantFiled: July 30, 2013Date of Patent: December 24, 2019Assignee: The Brigham and Women's Hospital, Inc.Inventors: Richard S. Blumberg, Vijay K. Kuchroo, Yu-Hwa Huang, Chen Zhu, Ana C. Anderson